The result of the study demonstrated that first-line EGFR TKI might be the reasonable care for advanced NSCLC patients harboring concomitant EGFR mutations and ALK rearrangements, but the result of the other study was conflicting, suggesting that ALK inhibitors appeared to be effective for patients with EGFR/ALK co-alterations [24]. Here, ALK is linked to non-small cell lung carcinoma.